Human Papillomavirus Vaccines versus Cervical Cancer Screening

Clinical Oncology

Volumn 20, Issue 6, 2008, Pages 388-394

  Stanley, M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cervical cancer; CIN; HPV; prophylactic vaccines; screening programmes; VLPs

Indexed keywords

ADJUVANT; ALUMINIUM HYDROXYPHOSPHATE SULPHATE; ALUMINUM HYDROXIDE; PHOSPHORYL LIPID A; PLACEBO; WART VIRUS VACCINE;

ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG TOLERABILITY; ENDOMETRIUM CARCINOMA; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; INFECTION RISK; PRIORITY JOURNAL; RISK ASSESSMENT; SEXUAL BEHAVIOR; UNITED KINGDOM; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS CARCINOGENESIS; VIRUS INFECTION; VIRUS LIKE AGENT;

CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; GREAT BRITAIN; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 46149096892     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2008.04.006     Document Type: Article

References (51)

1. Parkin D.M., and Bray F. The burden of HPV-related cancers. Vaccine 24 Suppl 3 (2006) S11-S25
2. Schlecht N.F., Kulaga S., Robitaille J., et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 286 (2001) 3106-3114
3. Liaw K.L., Hildesheim A., Burk R.D., et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 183 (2001) 8-15
4. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogen risks to humans. Human papillomaviruses vol. 64 (1995), World Health Organization International Agency for Research on Cancer, Lyon
5. Doorbar J. The papillomavirus life cycle. J Clin Virol 32 Suppl 1 (2005) S7-S15
6. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., and zur Hausen H. Classification of papillomaviruses. Virology 324 (2004) 17-27
7. Munoz N., Castellsague X., de Gonzalez A.B., and Gissmann L. HPV in the etiology of human cancer. Vaccine 24 Suppl 3 (2006) S1-S10
8. Lacey C.J., Lowndes C.M., and Shah K.V. Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 24 Suppl 3 (2006) S35-S41
9. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
10. Smith J.S., Lindsay L., Hoots B., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121 (2007) 621-632
11. Munoz N., Bosch F.X., de Sanjose S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
12. Koutsky L.A., Holmes K.K., Critchlow C.W., et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 327 (1992) 1272-1278
13. Clifford G.M., Smith J.S., Aguado T., and Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 89 (2003) 101-105
14. Munger K., Baldwin A., Edwards K.M., et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78 (2004) 11451-11460
15. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 9 (1999) 423-430
16. Carter J.J., Koutsky L.A., Hughes J.P., et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 181 (2000) 1911-1919
17. Shope R.E. Immunization of rabbits to infectious papillomatosis. J Exp Med 65 (1937) 607-624
18. Schiffman M., and Kjaer S.K. Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 31 (2003) 14-19
19. Pagliusi S.R., and Teresa Aguado M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 23 (2004) 569-578
20. Harper D.M., Franco E.L., Wheeler C., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
21. Harper D.M., Franco E.L., Wheeler C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
22. Joura E.A., Leodolter S., Hernandez-Avila M., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369 (2007) 1693-1702
23. Paavonen J., Jenkins D., Bosch F.X., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 (2007) 2161-2170
24. Garland S.M., Hernandez-Avila M., Wheeler C.M., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 (2007) 1928-1943
25. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (2007) 1915-1927
26. Ault K.A. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369 (2007) 1861-1868
27. Villa L.L., Ault K.A., Giuliano A.R., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 24 (2006) 5571-5583
28. Fraser C., Tomassini J.E., Xi L., et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 25 (2007) 4324-4333
29. Olsson S.E., Villa L.L., Costa R.L., et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25 (2007) 4931-4939
30. Giannini S.L., Hanon E., Moris P., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24 (2006) 5937-5949
31. Ni Y.H., Huang L.M., Chang M.H., et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology 132 (2007) 1287-1293
32. Hammitt L.L., Hennessy T.W., Fiore A.E., et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine 25 (2007) 6958-6964
33. Veiga A.P., Casseb J., and Duarte A.J. Humoral response to hepatitis B vaccination and its relationship with T CD45RA+ (naive) and CD45RO+ (memory) subsets in HIV-1-infected subjects. Vaccine 24 (2006) 7124-7128
34. Villa L.L., Costa R.L., Petta C.A., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 (2006) 1459-1466
35. Chen X.S., Garcea R.L., Goldberg I., Casini G., and Harrison S.C. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 5 (2000) 557-567
36. Smith J.F., Brownlow M., Brown M., et al. Antibodies from women immunized with Gardasil ((R)) cross-neutralize HPV 45 pseudovirions. Hum Vaccin 3 (2007) 109-115
37. Munoz N., Bosch F.X., Castellsague X., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111 (2004) 278-285
38. Hildesheim A., Herrero R., Wacholder S., et al. Effect of human papillomavirus 16/18 L1 virus-like particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298 (2007) 743-753
39. Peto J., Gilham C., Deacon J., et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 91 (2004) 942-953
40. Block S.L., Nolan T., Sattler C., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118 (2006) 2135-2145
41. Reisinger K.S., Block S.L., Lazcano-Ponce E., et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 26 (2007) 201-209
42. Raffle A.E. Challenges of implementing human papillomavirus (HPV) vaccination policy. Br Med J 335 (2007) 375-377
43. Bray F., Carstensen B., Moller H., et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 14 (2005) 2191-2199
44. Sasieni P., Adams J., and Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 89 (2003) 88-93
45. Herbert A., Holdsworth G., and Kubba A.A. Cervical screening: why young women should be encouraged to be screened. J Fam Plann Reprod Health Care 34 (2008) 21-25
46. Franco E.L., Cuzick J., Hildesheim A., and de Sanjose S. Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24 Suppl 3 (2006) S171-S177
47. Cuzick J., Clavel C., Petry K.U., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119 (2006) 1095-1101
48. Franco E.L., and Ferenczy A. Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination. Future Oncol 3 (2007) 319-327
49. Bosch F.X., Castellsague X., and de Sanjose S. HPV and cervical cancer: screening or vaccination?. Br J Cancer 98 (2008) 15-21
50. Kane M.A., Sherris J., Coursaget P., Aguado T., and Cutts F. HPV vaccine use in the developing world. Vaccine 24 Suppl 3 (2006) S132-S139
51. Denny L., Quinn M., and Sankaranarayanan R. Screening for cervical cancer in developing countries. Vaccine 24 Suppl 3 (2006) S71-S77